Takeda Sales Manager Urges 4th Circ. To Save FCA Case

Law360, New York (April 11, 2012, 3:22 PM EDT) -- A Takeda Pharmaceuticals North America Inc. sales leader told the Fourth Circuit on Monday that a lower court had wrongly dismissed his False Claims Act lawsuit alleging the drugmaker illegally sought federal reimbursement for excessive doses and unapproved uses of heartburn medication Kapidex.

In his qui tam suit, Takeda territory manager Noah Nathan says even though 90 percent of Kapidex prescriptions were for gastroesophageal reflux disease — for which only a 30-milligram dose is approved — more than 90 percent of Kapidex prescriptions were for 60-mg...
To view the full article, register now.